Literature DB >> 27313039

From the RNA world to the clinic.

Bruce A Sullenger1, Smita Nair1.   

Abstract

The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27313039      PMCID: PMC6035743          DOI: 10.1126/science.aad8709

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  39 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

Review 3.  RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Authors:  Maggie L Bobbin; John J Rossi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 5.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

Review 6.  The ReNAissanCe of mRNA-based cancer therapy.

Authors:  Sandra Van Lint; Dries Renmans; Katrijn Broos; Heleen Dewitte; Ine Lentacker; Carlo Heirman; Karine Breckpot; Kris Thielemans
Journal:  Expert Rev Vaccines       Date:  2014-09-29       Impact factor: 5.217

7.  Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.

Authors:  Yuyu Niu; Bin Shen; Yiqiang Cui; Yongchang Chen; Jianying Wang; Lei Wang; Yu Kang; Xiaoyang Zhao; Wei Si; Wei Li; Andy Peng Xiang; Jiankui Zhou; Xuejiang Guo; Ye Bi; Chenyang Si; Bian Hu; Guoying Dong; Hong Wang; Zuomin Zhou; Tianqing Li; Tao Tan; Xiuqiong Pu; Fang Wang; Shaohui Ji; Qi Zhou; Xingxu Huang; Weizhi Ji; Jiahao Sha
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

8.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

Review 9.  Fit for the Eye: Aptamers in Ocular Disorders.

Authors:  Daniel W Drolet; Louis S Green; Larry Gold; Nebojsa Janjic
Journal:  Nucleic Acid Ther       Date:  2016-01-12       Impact factor: 5.486

10.  Bevasiranib for the treatment of wet, age-related macular degeneration.

Authors:  Adinoyi O Garba; Shaker A Mousa
Journal:  Ophthalmol Eye Dis       Date:  2010-12-19
View more
  96 in total

1.  Current Progress in Electrotransfection as a Nonviral Method for Gene Delivery.

Authors:  Lisa D Cervia; Fan Yuan
Journal:  Mol Pharm       Date:  2018-06-20       Impact factor: 4.939

Review 2.  Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

Authors:  Roopesh S Gangwar; Sanjay Rajagopalan; Rama Natarajan; Jeffrey A Deiuliis
Journal:  Am J Hypertens       Date:  2018-01-12       Impact factor: 2.689

3.  Cleaning Up Mechanistic Debris Generated by Twister Ribozymes Using Computational RNA Enzymology.

Authors:  Colin S Gaines; Timothy J Giese; Darrin M York
Journal:  ACS Catal       Date:  2019-05-22       Impact factor: 13.084

Review 4.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 5.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 6.  The emergence of noncoding RNAs as Heracles in autophagy.

Authors:  Jian Zhang; Peiyuan Wang; Lin Wan; Shouping Xu; Da Pang
Journal:  Autophagy       Date:  2017-04-25       Impact factor: 16.016

7.  Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma.

Authors:  Chenming Zhao; Yuri Tolkach; Doris Schmidt; Marieta Toma; Michael H Muders; Glen Kristiansen; Stefan C Müller; Jörg Ellinger
Journal:  World J Urol       Date:  2018-11-28       Impact factor: 4.226

8.  Precision Tuning of DNA- and Poly(ethylene glycol)-Based Nanoparticles via Coassembly for Effective Antisense Gene Regulation.

Authors:  Dali Wang; Xueguang Lu; Fei Jia; Xuyu Tan; Xiaoya Sun; Xueyan Cao; Francesco Wai; Chuan Zhang; Ke Zhang
Journal:  Chem Mater       Date:  2017-11-18       Impact factor: 9.811

Review 9.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

Review 10.  Circular RNAs in thoracic diseases.

Authors:  Fan Yang; Ping Zhu; Jintao Guo; Xiang Liu; Sheng Wang; Guoxin Wang; Wen Liu; Shupeng Wang; Nan Ge
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.